Uncovering disparities in survival after non-small-cell lung cancer among Asian/Pacific Islander ethnic populations in California
- PMID: 19622719
- PMCID: PMC2764550
- DOI: 10.1158/1055-9965.EPI-09-0332
Uncovering disparities in survival after non-small-cell lung cancer among Asian/Pacific Islander ethnic populations in California
Abstract
Asians may have better survival after non-small-cell lung cancer (NSCLC) than non-Asians. However, it is unknown whether survival varies among the heterogeneous U.S. Asian/Pacific Islander (API) populations. Therefore, this study aimed to quantify survival differences among APIs with NSCLC. Differences in overall and disease-specific survival were analyzed in the California Cancer Registry among 16,577 API patients diagnosed with incident NSCLC between 1988 and 2007. Adjusted hazard ratios (HR) with 95% confidence intervals (95% CI) were estimated using Cox proportional hazards regression models with separate baseline hazards by disease stage. Despite better overall and disease-specific survival among APIs compared with non-Hispanic Whites, differences were evident across API populations. Among women, Japanese (overall survival HR, 1.16; 95% CI, 1.06-1.27) and APIs other than those in the six largest ethnic groups (other APIs; HR, 1.19; 95% CI, 1.07-1.33) had significantly poorer overall and disease-specific survival than Chinese. By contrast, South Asian women had significantly better survival than Chinese (HR, 0.79; 95% CI, 0.63-0.97). Among men, Japanese (HR, 1.15; 95% CI, 1.07-1.24), Vietnamese (HR, 1.07; 95% CI, 1.00-1.16), and other APIs (HR, 1.18; 95% CI, 1.08-1.28) had significantly poorer overall and disease-specific survival than Chinese. Other factors independently associated with poorer survival were lower neighborhood socioeconomic status, involvement with a non-university hospital, unmarried status, older age, and earlier year of diagnosis. APIs have significant ethnic differences in NSCLC survival that may be related to disparate lifestyles, biology, and especially health care access or use. To reduce the nationwide burden of lung cancer mortality, it is critical to identify and ameliorate hidden survival disparities such as those among APIs.
Similar articles
-
Survival following non-small cell lung cancer among Asian/Pacific Islander, Latina, and Non-Hispanic white women who have never smoked.Cancer Epidemiol Biomarkers Prev. 2011 Mar;20(3):545-54. doi: 10.1158/1055-9965.EPI-10-0965. Epub 2011 Jan 14. Cancer Epidemiol Biomarkers Prev. 2011. PMID: 21239685 Free PMC article.
-
Survival disparities in non-small cell lung cancer by race, ethnicity, and socioeconomic status.Cancer J. 2014 Jul-Aug;20(4):237-45. doi: 10.1097/PPO.0000000000000058. Cancer J. 2014. PMID: 25098282
-
Disparities in clinical and demographic characteristics among Asian/Pacific Islander and Non-Hispanic White newly diagnosed lung cancer patients.Cancer Causes Control. 2022 Apr;33(4):547-557. doi: 10.1007/s10552-021-01548-5. Epub 2022 Jan 19. Cancer Causes Control. 2022. PMID: 35043281
-
Disparities in Stage at Presentation for Disaggregated Asian American, Native Hawaiian, and Pacific Islander Patients with Breast Cancer.Ann Surg Oncol. 2025 May;32(5):3317-3330. doi: 10.1245/s10434-025-16974-x. Epub 2025 Mar 1. Ann Surg Oncol. 2025. PMID: 40025362
-
Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.Arch Phys Med Rehabil. 2008 Apr;89(4):595-601. doi: 10.1016/j.apmr.2007.09.042. Arch Phys Med Rehabil. 2008. PMID: 18373987 Review.
Cited by
-
Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health Initiative.J Clin Oncol. 2016 Feb 1;34(4):360-8. doi: 10.1200/JCO.2015.63.5789. Epub 2015 Dec 23. J Clin Oncol. 2016. PMID: 26700122 Free PMC article.
-
Racial disparities in non-small cell lung cancer survival outcomes: a systematic review and meta-analysis.Proc (Bayl Univ Med Cent). 2025 Jul 14;38(5):722-731. doi: 10.1080/08998280.2025.2524792. eCollection 2025. Proc (Bayl Univ Med Cent). 2025. PMID: 40821488 Free PMC article.
-
Comparative Analysis of Clinicopathologic Features of, Treatment in, and Survival of Americans with Lung or Bronchial Cancer.PLoS One. 2016 May 31;11(5):e0156617. doi: 10.1371/journal.pone.0156617. eCollection 2016. PLoS One. 2016. PMID: 27244238 Free PMC article.
-
A Validation Method to Determine Missing Years of Birth in a Cohort Study of Shipyard Workers Using Social Security Number.J Occup Environ Med. 2016 Jun;58(6):631-5. doi: 10.1097/JOM.0000000000000740. J Occup Environ Med. 2016. PMID: 27281641 Free PMC article.
-
Patient preference and contraindications in measuring quality of care: what do administrative data miss?J Clin Oncol. 2013 Jul 20;31(21):2716-23. doi: 10.1200/JCO.2012.45.7473. Epub 2013 Jun 10. J Clin Oncol. 2013. PMID: 23752110 Free PMC article.
References
-
-
Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969–2005) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008. Underlying mortality data provided by NCHS.
-
-
- Zell JA, Ou SH, Ziogas A, Anton-Culver H. Survival improvements for advanced stage nonbronchioloalveolar carcinoma-type nonsmall cell lung cancer cases with ipsilateral intrapulmonary nodules. Cancer. 2008;112:136–43. - PubMed
-
- Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet. 2005;366:1527–37. - PubMed
-
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132. - PubMed
-
- Sekine I, Nokihara H, Yamamoto N, et al. Common arm analysis: one approach to develop the basis for global standardization in clinical trials of non-small cell lung cancer. Lung Cancer. 2006;53:157–64. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical